default author photo

Francois Raffi

Centre Hospitalier Universitaire de Nantes

SCHOLARLY PAPERS

1

DOWNLOADS

70

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Switch to Dolutegravir/Rilpivirine in Virologically Suppressed, Antiretroviral Treatment-Experienced HIV-1 Infected Individuals with K103N Mutation: 48-Week Results of a Randomised, Pilot Clinical Trial

Number of pages: 23 Posted: 11 May 2023
Graeme Moyle, Lambert Assoumou, Nathalie De Castro, Frank A. Post, Adrià Curran, Stefano Russconi, Stephane De Wit, Christoph Stephan, Francois Raffi, Margaret Johnson, Mar Masiá, Jaime Vera, Bryn Jones, Richard Grove, Carl Fletcher, Annie Duffy, Kellie Morris, Anton Pozniak and NEAT ID Foundation WISARD (sWItch Study mutAtion Rilpivirine Dolutegravir) Study Group
Government of the United Kingdom - Chelsea and Westminster Hospital NHS Foundation Trust, Sorbonne University - Institut Pierre-Louis d'Epidémiologie et de Santé Publique, Université de Paris Cité - AP-HP, King’s College Hospital NHS Foundation Trust, Hospital Universitari Vall d’Hebron, University of Milan - DIBIC “Luigi Sacco”, Université Libre de Bruxelles (ULB) - CHU Saint-Pierre, Goethe University Frankfurt - University Hospital Frankfurt, Centre Hospitalier Universitaire de Nantes, Government of the United Kingdom - Royal Free London NHS Foundation Trust, Universidad Miguel Hernández de Elche, University of Sussex - Brighton and Sussex Medical School, ViiV Healthcare Ltd., GSK plc, Research Organisation (KC) LTD, Research Organisation (KC) LTD, Research Organisation (KC) LTD, Government of the United Kingdom - Chelsea and Westminster Hospital NHS Foundation Trust and Independent
Downloads 70 (875,328)

Abstract:

Loading...

dolutegravir/rilpivirine, switch, virological suppression, adverse event, K103N mutation